Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Oncternal Therapeutics, Inc is a biotechnology business based in the US. Oncternal Therapeutics shares (ONCT) are listed on the NASDAQ and all prices are listed in US Dollars. Oncternal Therapeutics employs 11 staff and has a trailing 12-month revenue of around USD$2.5 million.
|Latest market close||USD$4.39|
|52-week range||USD$1.49 - USD$7.19|
|50-day moving average||USD$4.0732|
|200-day moving average||USD$2.7781|
|Wall St. target price||USD$8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.81|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||N/A|
|1 month (2020-12-22)||-2.88%|
|3 months (2020-10-18)||N/A|
|6 months (2020-07-18)||N/A|
|1 year (2020-01-18)||N/A|
|2 years (2019-01-18)||N/A|
|3 years (2018-01-18)||N/A|
|5 years (2016-01-18)||N/A|
Valuing Oncternal Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Oncternal Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Oncternal Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Oncternal Therapeutics shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$2.5 million|
|Gross profit TTM||USD$-7,734,000|
|Return on assets TTM||-48.51%|
|Return on equity TTM||-111.22%|
|Market capitalisation||USD$234.1 million|
TTM: trailing 12 months
There are currently 384,940 Oncternal Therapeutics shares held short by investors – that's known as Oncternal Therapeutics's "short interest". This figure is 104.5% up from 188,220 last month.
There are a few different ways that this level of interest in shorting Oncternal Therapeutics shares can be evaluated.
Oncternal Therapeutics's "short interest ratio" (SIR) is the quantity of Oncternal Therapeutics shares currently shorted divided by the average quantity of Oncternal Therapeutics shares traded daily (recently around 7.7 million). Oncternal Therapeutics's SIR currently stands at 0.05. In other words for every 100,000 Oncternal Therapeutics shares traded daily on the market, roughly 50 shares are currently held short.
However Oncternal Therapeutics's short interest can also be evaluated against the total number of Oncternal Therapeutics shares, or, against the total number of tradable Oncternal Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oncternal Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Oncternal Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0087% of the tradable shares (for every 100,000 tradable Oncternal Therapeutics shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oncternal Therapeutics.
Find out more about how you can short Oncternal Therapeutics stock.
We're not expecting Oncternal Therapeutics to pay a dividend over the next 12 months.
Oncternal Therapeutics's shares were split on a 1:7 basis on 10 June 2019. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oncternal Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Oncternal Therapeutics shares which in turn could have impacted Oncternal Therapeutics's share price.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ROR1) that is in Phase I/II clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in Phase Ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. It also develops TK-216, a small-molecule that is designed to inhibit E26 transformation specific family of oncoproteins, which is in Phase I clinical trial to treat patients with Ewing sarcoma and in combination with vincristine chemotherapy. In addition, the company develops a chimeric antigen receptor-T product candidate that targets ROR1, which is in preclinical development for treating hematologic cancers and solid tumors. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Everything we know about the NLS Pharmaceutics Ltd IPO, plus information on how to buy in.
Everything we know about the GitLab IPO, plus information on how to buy in.
Everything we know about the Longeveron LLC IPO, plus information on how to buy in.
Everything we know about the Signify Health Inc IPO, plus information on how to buy in.
Everything we know about the Biophytis SA IPO, plus information on how to buy in.
Everything we know about the NexImmune Inc IPO, plus information on how to buy in.
Everything we know about the Adagene Inc IPO, plus information on how to buy in.
Everything we know about the Cloopen Group Holding Limited IPO, plus information on how to buy in.
Everything we know about the Decipher Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Proterra IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.